U.S. markets closed
  • S&P Futures

    4,199.75
    -23.25 (-0.55%)
     
  • Dow Futures

    33,847.00
    -170.00 (-0.50%)
     
  • Nasdaq Futures

    13,878.50
    -102.75 (-0.73%)
     
  • Russell 2000 Futures

    2,291.30
    -18.80 (-0.81%)
     
  • Crude Oil

    71.53
    -0.62 (-0.86%)
     
  • Gold

    1,818.20
    -43.20 (-2.32%)
     
  • Silver

    27.26
    -0.55 (-1.98%)
     
  • EUR/USD

    1.1992
    -0.0009 (-0.07%)
     
  • 10-Yr Bond

    1.5690
    +0.0700 (+4.67%)
     
  • Vix

    18.15
    +1.13 (+6.64%)
     
  • GBP/USD

    1.3980
    -0.0007 (-0.05%)
     
  • USD/JPY

    110.7810
    +0.1680 (+0.15%)
     
  • BTC-USD

    38,600.82
    -1,359.14 (-3.40%)
     
  • CMC Crypto 200

    956.55
    -35.92 (-3.62%)
     
  • FTSE 100

    7,184.95
    +12.47 (+0.17%)
     
  • Nikkei 225

    29,033.61
    -257.40 (-0.88%)
     

Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that members of the executive management team will participate in multiple upcoming investor conferences including the:

  • Cowen 41st Annual virtual Healthcare Conference fireside chat on Thursday, March 4, 2021 at 2:10 p.m. ET;

  • H.C. Wainwright Global Life Sciences Conference fireside chat available on Tuesday, March 9, 2021 at 7:00 a.m. ET; and

  • Oppenheimer’s 31st Annual Healthcare Conference presentation on Wednesday, March 17, 2021 at 10:40 a.m. ET.

In order to participate in the audio webcast, interested parties can access the live webcast under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

ABOUT AURINIA

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company has introduced LUPKYNIS™ (voclosporin), the first FDA-approved oral therapy dedicated for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005227/en/

Contacts

Investor Contact:
Glenn Schulman, PharmD, MPH
SVP, Corporate Communications & IR
gschulman@auriniapharma.com